Form 4: MiMedx Director Todd Newton Receives Stock Grant

Director Todd Newton acquired 50,913 shares of MiMedx Group, Inc. common stock as part of an annual restricted stock grant.

Summary

• Director Todd Newton was granted 50,913 shares of MiMedx Group, Inc. (MDXG) common stock.
• The transaction occurred on June 10, 2026, at a price of $3.64 per share.
• Following this transaction, the director's total beneficial ownership increased to 463,684 shares.
• The grant is classified as an annual restricted stock award for non-employee directors.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of market impact.

Positives

• Alignment of director interests with shareholders through increased equity ownership.
• Standard compensation practice for non-employee directors.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

The restricted stock award vests upon the earlier of 12 months from the grant date or the next meeting of shareholders.

Industry Context

StockSavvy.ai notes that annual equity grants to non-employee directors are a standard corporate governance practice in the biotechnology and medical device sectors to ensure long-term alignment with shareholder value.

Comparison to Industry Standards

• The grant structure is consistent with standard equity compensation packages for board members in mid-cap healthcare companies.
• The vesting schedule (12 months or next annual meeting) aligns with typical industry practices for director retention.

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal impact; reflects standard director compensation.

Next Steps

• Vesting of the 50,913 shares in 12 months or at the next shareholder meeting.

Key Dates

Keywords

MiMedx, MDXG, Form 4, Insider Trading, Director Compensation, Equity Grant